Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128239 | 0.89 | CTSS (0.47) | CTSSCTSKALDH1A1L3MBTL1POLB | |
| SCHEMBL12466119 | 0.89 | CTSS (0.47) | CTSSCTSKALDH1A1L3MBTL1POLB | |
| SCHEMBL22346401 | 0.84 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL7432219 | 0.77 | PSENEN (0.43) | CTSSCTSKALDH1A1POLBPSENEN | |
| SCHEMBL7432224 | 0.77 | PSENEN (0.43) | CTSSCTSKALDH1A1POLBPSENEN | |
| SCHEMBL15674495 | 0.76 | CTSS (0.35) | CTSSCTSKALDH1A1L3MBTL1POLB | |
| SCHEMBL22346381 | 0.76 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL3958728 | 0.76 | CTSK (0.42) | CTSSCTSKKMT2AMEN1CYP2D6 | |
| SCHEMBL16894118 | 0.76 | CTSK (0.42) | CTSSCTSKKMT2AMEN1CYP2D6 | |
| SCHEMBL4372563 | 0.76 | CTSK (0.42) | CTSSCTSKKMT2AMEN1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132386-A9 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2023-04-27 | — | — | US | disclosed |
| US-20220135593-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC (US) | 2022-05-05 | — | — | US | disclosed |
| EP-3924354-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | Cytosite Biopharma Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020167989-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132386-A9 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | CTSS 65/4885CTSK 24/4885ALDH1A1 4151/4885 |
| US-20220135593-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | CTSS 65/4885CTSK 24/4885ALDH1A1 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.